Grapevine Research and Clinical Trials

STAR Infigratinib vs Gem/Cis Cholangio

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301) Read More

Phase: III

FLEX Registry: Evaluate New Gene Express

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read More

Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial

Phase: III

Ph 3 Tuca/Placbo + T-DM1 HER2+

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016) Read More

Phase: III

Ph2 Cervical 2L (RaPiDS)

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028) Read More

Phase: II

PH3 Plac Carbo Pacil Dura +/- Olap DUO-E

D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) Read More

Phase: III

STAR PH3 Pacritinib vs MD choice in MF

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203) Read More

Phase: III

STAR Infigratinib vs Gem/Cis Cholangio

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301) Read More

Phase: III

Ublituximab+TGR-1202 Cross-over

(UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304 Read More

Phase: II

STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789) Read More

Phase: III

STAR-PH3 pral(Blu-667) RET-fusion mNSCLC

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303) Read More

Phase: III

STAR BV in older pts w/1L cHL or PTCL

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy Read More

Phase: II

EAP BGB-3111 B-Cell Malig

A Single-Arm, Expanded Access Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies (BGB-3111-216) Read More

STAR PH3 Pacritinib vs MD choice in MF

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician''s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203) Read More

Phase: III

PANOVA-3: 1L Gemcit + nab-pac pancreatic

PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27) Read More

Phase: III

STAR Abirat+pred +/- abemaciclib mCRPC

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM) Read More

Phase: II

STAR Ph3 Nirap+Abirat+Pred mCRPC

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001) Read More

Phase: III

STAR Rucaparib v PhysC mCRPC (TRITON3)

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063) Read More

Phase: III

STAR Ph2 Pemigatinib Solids FGFR

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Read More

Phase: II

STAR Ph2 Erdafitinib FGFR Solid Tumors

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002) Read More

Phase: II

STAR Ph3 FGFR erdafitinib urothelial

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) Read More

Phase: III